This meant building a team of anywhere from ten to fifty people to deal with all the complexities of the process: chemistry, biology, regulatory affairs, clinical medicine, finance, business development, patent strategy, etc.
Instead of focusing on whether a longtime hustler with a history of making grandiose statements about his scientific process could really defy the laws of physics and chemistry, the SEC should have spent its time figuring out who facilitated the sale of so much worthless stock on the open market.